Oculis Holding AG (Nasdaq: OCS; XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of USD 110 million. Oculis Holding AG intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes. VISCHER AG is representing Oculis Holding AG in this financing for Swiss legal matters with Matthias Staehelin, Vincent Reardon, Balthasar Müller and Elena Weller (all Corporate/M&A) as well as Nadia Tarolli Schmidt and Patrik Fisch (both Tax).
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
Nadia Tarolli Schmidt
Attorney at Law, Swiss Certified Tax Expert
- Partner
- +41 58 211 33 54
- [email protected]
